Merck's (MRK +0.3%) insomnia drug suvorexant maintained its effectiveness for 12 months in a...


Merck's (MRK +0.3%) insomnia drug suvorexant maintained its effectiveness for 12 months in a late-stage study. Suvorexant is one of 6 treatments that Merck will seek FDA approval for in 2012 and 2013 as it looks to compensate for the upcoming loss of patent protection for its blockbuster asthma treatment Singulair.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs